|Bid||38.61 x 800|
|Ask||40.50 x 800|
|Day's range||38.90 - 40.98|
|52-week range||19.38 - 87.24|
|Beta (5Y monthly)||2.23|
|PE ratio (TTM)||N/A|
|Earnings date||08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||86.21|
Are you looking for biotech stocks that could shoot higher? Wall Street analysts who cover the stocks on this list think they could provide some eye-popping gains. Every stock on this list has a consensus price target that's 91% above its present price.
Shares of the developmental-stage biotech Axsome Therapeutics (NASDAQ: AXSM) vaulted higher by a healthy 25% through Thursday's close this week, according to data from S&P Global Market Intelligence. The U.S. Food and Drug Administration (FDA) still hasn't issued a regulatory decision for the company's major depressive disorder drug candidate known as AXS-05. Axsome posted several job openings on its website and other social media sites, indicating a need for individuals to work on AXS-05's commercial launch.
The biotech industry is an excellent place to start. Clinical trial victories and regulatory approvals can send shares of a biotech soaring, especially one with a relatively small stock market capitalization. Let's look closer at one biotech whose shares have been hammered over the past few months, Axsome Therapeutics (NASDAQ: AXSM), and consider why this company still has some serious potential.